Laden…
Synapedia is an independent knowledge project about psychoactive substances and harm reduction. If the platform helps you learn something new, you can support its development.
Every bit helps keep the project alive.
Substance Comparison
Cannabis / THC and CBD are both classified as Cannabinoide. Available data suggests they share activity at CB1. Cannabis / THC is commonly associated with a moderate risk profile compared to CBD.
Both substances belong to the Cannabinoide class, making this a common comparison for understanding differences within the same pharmacological family.
No significant profile differences
| Cannabis / THC | CBD | |
|---|---|---|
| Class | Cannabinoide | Cannabinoide |
| Risk Level | moderate | low |
| Mechanisms | CB1-Agonist, CB2-Agonist | CB1-negativer allosterischer Modulator, 5-HT1A-Agonist |
| Receptors | CB1, CB2 | CB1, 5-HT1A |
| Effects | — | Beeinflussung des Appetits, Müdigkeit, Durchfall, Schmerzlinderung, Reduktion von Angstzuständen |
| Evidence | — | moderate |
Cannabidiol (CBD) hat eine komplexe Pharmakologie mit mehreren Zielstrukturen. KRITISCH: CBD bindet NICHT signifikant an CB1- oder CB2-Endocannabinoid-Rezeptoren. Primäre Mechanismen: (1) 5-HT1A-Partialagonismus (anxiolytisch, antidepressiv), (2) TRPV1-Kanal-Agonismus (analgetisch, neuroprotektiv), (3) Negativer allosterischer Modulator am CB1-Rezeptor (dämpft THC-Effekte), (4) GPR55-Antagonismus (antiepileptisch), (5) Adenosin-Transporter-Inhibition (antiinflammatorisch), (6) FAAH-Inhibition (Erhöhung endogener Anandamid-Spiegel). CBD ist auch ein schwacher CYP2C19- und CYP3A4-Inhibitor mit klinischen Arzneimittelinteraktions-Implikationen.
No harm reduction data available
Safer-use data available on substance page
Evidence: not assessed · Sources: 2
Evidence: moderate · Sources: 5